|Bioavailability||Peak plasma levels occur within 1 to 3 hours. Absorption is usually complete by 4 to 6 hours|
|Elimination half-life||19-24 hours|
|CompTox Dashboard (EPA)|
|ECHA InfoCard||100.010.186 |
|Chemical and physical data|
|Molar mass||191.27 g/mol g·mol−1|
|3D model (JSmol)|
Phendimetrazine functions as a prodrug to phenmetrazine; approximately 30 percent of an oral dose is converted into it. Phendimetrazine can essentially be thought of as an extended-release formulation of phenmetrazine with less potential for abuse. Phenmetrazine acts as a norepinephrine-dopamine releasing agent (NDRA).
Its structure incorporates the backbone of methamphetamine, a potent CNS stimulant. While the addition of an N-methyl group to amphetamine significantly increases its potency and bioavailability, methylation of phendimetrazine renders the compound virtually inactive. Metabolization by demethylases produces a steady, continuous activation of the drug in the body, both lowering abuse potential and allowing for once-daily administration.
According to the List of Psychotropic Substances under International Control published by the International Narcotics Control Board, phendimetrazine is a Schedule III controlled substance under the Convention on Psychotropic Substances.
- Landau D, Jackson J, Gonzalez G (2008). "A case of demand ischemia from phendimetrazine". Cases J. 1 (1): 105. doi:10.1186/1757-1626-1-105. PMC 2531092. PMID 18710555.
- Rothman RB, Baumann MH (2006). "Therapeutic potential of monoamine transporter substrates". Current Topics in Medicinal Chemistry. 6 (17): 1845–59. doi:10.2174/156802606778249766. PMID 17017961.
- List of psychotropic substances under international control